A three-gene signature might predict prognosis in patients with acute myeloid leukemia

Abstract

The identification of effective signatures is crucial to predict the prognosis of acute myeloid leukemia (AML). The investigation aimed to identify a new signature for AML prognostic prediction by using the three-gene expression (octamer-binding transcription factor 4 (OCT4), POU domain type 5 transcription factor 1B (POU5F1B) and B-cell-specific Moloney murine leukemia virus integration site-1 pseudogene 1 (BMI1P1). The expressions of genes were obtained from our previous study. Only the specimens in which three genes were all expressed were included in this research. A three-gene signature was constructed by the multivariate Cox regression analyses to divide patients into high-risk and low-risk groups. Receiver operating characteristic (ROC) analysis of the three-gene signature (area under ROC curve (AUC) = 0.901, 95% CI: 0.821–0.981, P<0.001) indicated that it was a more valuable signature for distinguishing between patients and controls than any of the three genes. Moreover, white blood cells (WBCs, P=0.004), platelets (PLTs, P=0.017), percentage of blasts in bone marrow (BM) (P=0.011) and complete remission (CR, P=0.027) had significant differences between two groups. Furthermore, high-risk group had shorter leukemia-free survival (LFS) and overall survival (OS) than low-risk group (P=0.026; P=0.006), and the three-gene signature was a prognostic factor. Our three-gene signature for prognosis prediction in AML may serve as a prognostic biomarker.

The World of Pseudogenes: New Diagnostic and Therapeutic Targets in Cancers or Still Mystery Molecules?

“…In the abdomen and bones area, 73 pseudogenes in such cancers as bladder carcinoma, cervical carcinoma, colorectal cancer, osteosarcoma, and more, in tissue, plasma, blood, and urine samples have been indicated. In the tissues of acute myeloid leukemia patients, BMI1P1A, OCT4, and POU5F1B are three gene signatures that divide individuals into high-risk and low-risk groups [44]. PA2G4P4 is overexpressed in bladder cancer patient tissues and cell lines [45].…”

A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction

“…4,7 Within this context, the identification of markers that could improve the risk prediction is an unmet medical need. 5,6 Several groups have worked on the identification of these markers using transcriptome data, mainly based on microarray and RNA-sequencing technologies, [8][9][10][11][12][13][14][15][16][17][18][19] showing that gene expression profiles can be valuable for risk stratification. However, until today, no gene signature based on gene expression has been incorporated into any risk classification system, mainly due to a lack of validation or reproducibility.…”